Patents Examined by Johnnie R. Brown
  • Patent number: 5190927
    Abstract: A partially deacylated gellan gum which forms elastic gels having low brittleness, and a process for its preparation.
    Type: Grant
    Filed: July 9, 1991
    Date of Patent: March 2, 1993
    Assignee: Merck & Co., Inc.
    Inventors: Helena C. Chang, Joseph M. Kobzeff
  • Patent number: 5190863
    Abstract: A composition, test device and method of determining the presence or concentration of ketone bodies, and specifically D-.beta.-hydroxybutyrate, in a test sample are disclosed. The test device includes a test pad comprising a suitable carrier matrix incorporating an indicator reagent composition capable of interacting with D-.beta.-hydroxybutyrate to produce a detectable or measurable response. In addition, a new and improved indicator reagent composition, comprising a) an indicator dye that is responsive to thiols, such as a substituted isobenzothiazolone, Ellman's reagent or a derivative of Ellman's reagent; b) D-.beta.-hydroxybutyrate dehydrogenase; c) lipoamide dehydrogenase; d) D,L-lipoamide; and e) nicotinamide adenine dinucleotide, is incorporated into the carrier matrix to provide an accurate and sensitive assay of a test sample for D-.beta.-hydroxybutyrate (DHBA) in particular, and for ketone bodies in general.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: March 2, 1993
    Assignee: Miles Inc.
    Inventor: Thomas A. Magers
  • Patent number: 5189017
    Abstract: Described are the use of hexopyranose compounds of the formula I ##STR1## for the prophylaxis and treatment of virus infections, and novel pharmaceutical preparations especially suitable for the use in accordance with the invention.The substituents in formula I have the meanings given in the claims.
    Type: Grant
    Filed: October 17, 1990
    Date of Patent: February 23, 1993
    Assignee: Ciba-Geigy Corporation
    Inventors: Bohumir Lukas, Karl H. Schmidt-Ruppin
  • Patent number: 5189151
    Abstract: An oligonucleotide comprises a DNA segment capable of hybridizing to DNA from enteroaggregative E. coli bacteria with high sensitivity and specificity. A recombinant vector comprises a vector carrying the oligonucleotide of the invention, the vector being capable of replication in a host. A host is transformed with the recombinant vector of the invention. A method of detecting the presence of enteroaggregative E. coli DNA in a biological sample with high sensitivity and specificity comprises adding to the sample the labeled oligonucleotide of the invention under conditions effective to promote hybridization thereof to the sample's DNA, and detecting the presence of hybridized labeled DNA. A method of detecting the presence of enteroaggregative E. coli RNA in a sample with high sensitivity and specificity comprises adding to the sample the oligonucleotide of the invention under conditions effective to promote hybridization thereof to the sample's RNA and detecting the presence of hybridized labeled RNA-DNA.
    Type: Grant
    Filed: May 16, 1990
    Date of Patent: February 23, 1993
    Inventors: Bernadette Baudry, Myron M. Levine
  • Patent number: 5188942
    Abstract: A rapid, competitive enzyme linked immunosorbent assay (cELISA) for the determination of Bluetongue virus antibodies in serum is described. This method utilizes either a biotinylated monoclonal antibody to Bluetongue virus and streptavadin-enzyme in conjunction with synthetic substrate, or an enzyme-conjugated monoclonal to detect antibodies specific for Bluetongue virus.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: February 23, 1993
    Assignee: Consultants for Applied Biosciences, Inc.
    Inventors: John J. Reddington, Ginger M. Reddington
  • Patent number: 5188851
    Abstract: A feed composition for fish breeding with an improved preference for fish comprises from 0.03 to 1% by weight of each of 5'-guanylic acid, 5'-cytidylic acid, 5'-uridylic acid and 5'-adenylic acid or 5'-inosinic acid, all of which are hydrolyzates of ribonucleic acid, or a yeast extract containing a large amount of the foregoing 5'-nucleotides and oligopeptide.
    Type: Grant
    Filed: November 20, 1990
    Date of Patent: February 23, 1993
    Assignee: Sanyo-Kokusaku Pulp Co., Ltd.
    Inventors: Katsuhiro Mamoto, Yasuyuki Nakamura, Akiyoshi Kawaoka, Masahiko Tabata
  • Patent number: 5188897
    Abstract: Optically active compounds of the formula ##STR1## wherein n is 1 or 2 and m is 0, 1, 2 or 3 have antiviral activity. Compounds of the formula wherein at least one of the internucleotide phosphorothioate linkages isREFERENCE TO GOVERNMENT GRANTThe invention described herein was made, in part, in the course of work supported by National Institutes of Health grant PO1 CA-29545 and National Science Foundation grant DMB84-15002.
    Type: Grant
    Filed: March 26, 1990
    Date of Patent: February 23, 1993
    Assignee: Temple University of the Commonwealth System of Higher Education
    Inventors: Robert J. Suhadolnik, Wolfgang Pfleiderer
  • Patent number: 5189150
    Abstract: Novel macrolactones with pharmacological effects can be prepared with the aid of Streptoverticillium and Streptomycetes strains.
    Type: Grant
    Filed: October 24, 1991
    Date of Patent: February 23, 1993
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Axel Zeeck, Siegrid Philipps, Susanne Grabley, Ernold Granzer, Klaus Hutter, Ralf Thiericke, Joachim Wink
  • Patent number: 5189027
    Abstract: Disclosed herein are a novel 2-substituted adenosine derivative having the following formula [I] ##STR1## wherein R represents a hydrogen atom or a hydroxyl group, m is an integer of 2 to 7, n is 0 or an integer of 1 to 3, and R.sup.1, R.sup.2 and R.sup.3, which may be the same or different, each independently represent a hydrogen atom, a hydroxy protective group or a phosphoric acid residue, and salts thereof.The above compounds are excellent in a circulation ameliorating effect such as a vasodepressor activity, and have high selectivity for A.sub.2 receptors, but cause less undesirable side effects such as a suppresssive effect on the heart. They are therefore effective when used in pharmaceutical compositions for circulatory diseases.
    Type: Grant
    Filed: November 27, 1991
    Date of Patent: February 23, 1993
    Assignee: Yamasa Shoyu Kabushiki Kaisha
    Inventors: Takanori Miyashita, Toichi Abiru, Yohko Watanabe, Toyofumi Yamaguchi, Akira Matsuda
  • Patent number: 5187070
    Abstract: An improved assay for the determination for motile facultative anaerobic pathogens is described which involves the use of a growth-enhancing substance such as oxyrase enzyme in order to increase the growth rate of a target pathogen in a growth medium, to thereby shorten the time required to complete the assay. The assay of the invention is particularly suited for the determination of L. monocytogenes in food products such as meat and dairy goods, and provides and effective screening assay which can be completed in about 24-36 hours. Preferably, a product sample is first incubated in Fraser Broth containing oxyrase enzyme; if a darkened color results, a small portion of the liquid is then placed within a U-shaped culture tube provided with modified Oxford agar; the motility characteristics of the target pathogen are observed in the U-tube, which is indicative of the presence of L. monocytogenes.
    Type: Grant
    Filed: October 9, 1990
    Date of Patent: February 16, 1993
    Assignee: Kansas State University Research Foundation
    Inventors: Daniel Y. C. Fung, Linda Yu
  • Patent number: 5186933
    Abstract: A method to express rotavirus genes in a baculovirus system. Different clones are used to express rotavirus genes for all of the viral proteins. These proteins are isolated in their native conformation. Some of these proteins show antigenic properties and are used to vaccinate human, agricultural animals and pet animals against diarrheal disease. The antigenic proteins are also used to detect the presence of the viral infectious agent either by themselves or in conjunction with antibodies produced against the antigenic proteins.
    Type: Grant
    Filed: December 30, 1986
    Date of Patent: February 16, 1993
    Assignee: Baylor College of Medicine
    Inventor: Mary K. Estes
  • Patent number: 5187163
    Abstract: Novel anti-viral compounds comprise phosphate-linked dimers of anti-viral nucleoside derivatives, or salts or esters of such nucleoside dimers. Pharmaceutical compositions containing the dimers and methods of treatment utilizing the same are disclosed.
    Type: Grant
    Filed: January 28, 1992
    Date of Patent: February 16, 1993
    Assignee: Baker Norton Pharmaceuticals, Inc.
    Inventors: Phillip Frost, Jack Fishman, Elliot Hahn, Jing J. Lu
  • Patent number: 5185146
    Abstract: The present invention relates to recombinant vaccinia viruses which are derived from the modified virus Ankara (MVA) and which contain a DNA sequence which codes for a foreign antigen. The invention also relates to vaccines which contain a virus of this type in a form suitable for injection, as well as to a method for the preparation thereof. Furthermore, the invention relates to the use of a recombinant vaccinia virus MVA for the preparation of heterologous proteins in eukariotic cells.
    Type: Grant
    Filed: January 4, 1989
    Date of Patent: February 9, 1993
    Assignee: Hoffmann-LaRoche Inc.
    Inventor: Werner Altenburger
  • Patent number: 5185437
    Abstract: This invention relates to certain 6-substituted 2',3'-dideoxypurine nucleosides and pharmaceutically acceptable derivatives thereof and their use in the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infections. Also provided are pharmaceutical formulations and processes for the production of the compounds of the invention.
    Type: Grant
    Filed: August 31, 1991
    Date of Patent: February 9, 1993
    Assignee: Burroughs Wellcome Co.
    Inventors: George W. Koszalka, Charlene L. Burns, Thomas A. Krenitsky, Janet L. Rideout
  • Patent number: 5185327
    Abstract: A new glucan derivative having at least one side chain branch of a compound selected from the group consisting of galactopyranose, L-arabinofuranose and oligomers thereof is disclosed. These glucan derivatives have high tumoricidal activity and are usable as a tumoricide.
    Type: Grant
    Filed: August 24, 1990
    Date of Patent: February 9, 1993
    Assignee: Ajinomoto Company, Inc.
    Inventors: Kei Matsuzaki, Iwao Yamamoto, Akira Misaki, Yoshiaki Sone
  • Patent number: 5185165
    Abstract: A precursor base for use in a bakery dough product comprising an acidic concentrate, at least one type of sugar, yeast, at least one type of flour, non-fat dry milk and at least one type of lactic acid producing bacteria and a process for producing the precursor base are disclosed. The precursor base is useful in a process for producing a precursor slurry (or active ferment concentrate) for use in making a preferment dough mixture for the preparation of the bakery dough product. In addition, processes for preparing the precursor slurry and the preferment dough mixture and an apparatus for producing the preferment dough mixture are disclosed.
    Type: Grant
    Filed: January 23, 1989
    Date of Patent: February 9, 1993
    Assignee: Superior Fermitech Liquidating Trust
    Inventor: Charles C. Lynn
  • Patent number: 5183658
    Abstract: The present invention relates to Hantaan virus and a vaccine therefor. The Hantaan virus vaccine can be prepared as follows: The Hantaan virus ROK84/105 strain isolated from the human body as a seed strain, injected to one-day-old suckling mouse or rat, which is raised for about 10 days. Thereafter, the head of the mouse or rat is cut apart after paralyzing the mouse or rat to take the brain, the brain is treated with ethyl alcohol and protamine sulfate solution, the resultant is purified and inactivated, and an adjuvant is added to the final product.
    Type: Grant
    Filed: November 16, 1989
    Date of Patent: February 2, 1993
    Assignee: Korea Green Cross Corporation
    Inventors: Ho W. Lee, Sun J. Riu, Chang N. An
  • Patent number: 5183808
    Abstract: Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.
    Type: Grant
    Filed: February 19, 1992
    Date of Patent: February 2, 1993
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yosuke Sawada, Masatoshi Kakushima, Maki Nishio, Takeo Miyaki, Toshikazu Oki
  • Patent number: 5183659
    Abstract: A new bacterial vaccine to protect susceptible equine against S. equi which causes strangles. The vaccine stimulates a nasopharyngeal immune response in a susceptible equine through the presence of antibody activity in the nasopharyngeal mucus. The vaccine is a S. equi strain which contains an M protein fragment of 41,000 mw and is adapted for administration to equine either intranasally or orally as a vaccine. There is described a new strain of S. equi (709-27), a method of making and isolating useful vaccine strain of S. equi bacteria which stimulates an antibody response in the nasopharyngeal mucosa of the susceptible equine.
    Type: Grant
    Filed: June 15, 1988
    Date of Patent: February 2, 1993
    Assignee: Cornell Research Foundation, Inc.
    Inventor: John F. Timoney
  • Patent number: 5182374
    Abstract: An improved process for producing the antibiotic compound clindamycin phosphate through the use of novel intermediate, 7(S)-chloro-7-deoxylincomycin-2-bis(2,2,2-trichloroethyl)phosphochloridate and similar compounds.
    Type: Grant
    Filed: March 21, 1990
    Date of Patent: January 26, 1993
    Assignee: American Cyanamid Company
    Inventors: Martin Tobkes, Simon Diaz, Lalitha Krishnan